AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)
Primary analysis is a success and confirms interim analysis
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), on March 20th announced that the phase 2/3 study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS) has met its pre-specified primary endpoint.
Study AB10015 was a double-blind, placebo-controlled phase 2/3 study to compare the efficacy and safety of masitinib in combination with riluzole, versus placebo in combination with riluzole in the treatment of
patients suffering from ALS.
Further deitails on the study are available on the company press release
http://www.ab-science.com/en/news